Bryan Kobel's guest appearances

Bryan Kobel

Stock Day Media

BioTech IQ

Cell & Gene: The Podcast

OwlTail

The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ:TCBP)(“the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. CEO of the Company, Bryan Kobel, joined Stock Day host Kevin Davis.

TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast

Bryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals.Support the show! https://www.buymeacoffee.com/biotechiqSupport the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/

<a href="https://www.linkedin.com/in/bryan-kobel-330a197/" rel="nofollow" target="_blank">Bryan Kobel</a> decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of <a href="https://tcbiopharm.com/" rel="nofollow" target="_blank">TC BioPharm</a>, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals. Support the show! <a href="https://www.buymeacoffee.com/biotechiq" rel="nofollow" target="_blank">https://www.buymeacoffee.com/biotechiq</a><a href="https://www.buzzsprout.com/1208600/support" rel="payment nofollow" target="_blank">Support the show</a>Check me out on LinkedIn <a href="https://www.linkedin.com/in/ammonr/" rel="nofollow" target="_blank">https://www.linkedin.com/in/ammonr/</a>

#65. A Journey From Investment Banker To The CEO Of A Biotech Developing Cancer Therapy With Bryan Kobel

TC BioPharm's CEO Bryan Kobel explains gamma delta t cells (GDT) in depth as well as the advantages of using GDT cells as a cell therapy vehicle. He discusses why the publicly-traded, clinical-stage cell therapy company conducts and manages all clinical trials in house as well as the unique challenges and benefits that come along with doing so. 

TC BioPharm's CEO Bryan Kobel explains gamma delta t cells (GDT) in depth as well as the advantages of using GDT cells as a cell therapy vehicle. He discusses why the publicly-traded, clinical-stage cell therapy company conducts and manages all clinical trials in house as well as the unique challenges and benefits that come along with doing so.